Evidence map›Paper›PMID 36341170›Full record

ArticleJIMD reports2022

Severe loss of appetite and refusal to eat as severe side effect of glycerol phenylbutyrate.

Sarah Catharina Grünert, Anke Schumann, Ute Spiekerkoetter

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JIMD reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sarah Catharina GrünertDepartment of General Pediatrics, Adolescent Medicine and Neonatology Medical Center-University of Freiburg, Faculty of Medicine Freiburg Germany.ORCID https://orcid.org/0000-0001-5986-0468
Anke SchumannDepartment of General Pediatrics, Adolescent Medicine and Neonatology Medical Center-University of Freiburg, Faculty of Medicine Freiburg Germany.
Ute SpiekerkoetterDepartment of General Pediatrics, Adolescent Medicine and Neonatology Medical Center-University of Freiburg, Faculty of Medicine Freiburg Germany.
University of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycerol phenylbutyrate (GPB) is an ammonia scavenger drug commonly used in the therapy of patients with urea cycle defects. Reported side effects include body odor, abdominal pain, nausea, burning sensation in mouth, vomiting, and heartburn. We report on a 3-year-old late diagnosed female patient with ornithine transcarbamylase deficiency that experienced severe loss of appetite under treatment with GBP. Due to catabolism (calory intake about 400 kcal/day) and the associated risk of metabolic decompensation, GBP treatment was discontinued. Her appetite and eating behavior normalized within 1 day after discontinuation of GBP and switch to sodium benzoate. Our case demonstrates that GBP can cause severe loss of appetite that may put patients at risk of metabolic decompensation and require discontinuation of therapy.

Indexed as

glycerol phenylbutyrateloss of appetiteornithine transcarbamylase deficiencyRavicti®urea cycle defect

Identifiers

PMID36341170
PMCPMC9626662
OpenAlexW4298142536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.